Functional Changes of Orexinergic Reaction to Psychoactive Substances

Area of Science:

• Neuroscience
• Pharmacology
• Metabolic Research

Background:

• The central nervous system (CNS) plays a key role in regulating systemic metabolism.
• Antipsychotic medications, particularly second-generation antipsychotics (SGAs), are associated with substantial weight gain and obesity.
• Psychiatric disorders themselves increase the risk of metabolic complications.

Purpose of the Study:

• To investigate the influence of orexin A on sympathetic and hyperthermic responses to various neuroleptic drugs.
• To explore the role of the orexinergic system in mediating the body temperature effects of neuroleptic medications.
• To inform therapeutic strategies for managing metabolic side effects of antipsychotics.

Main Methods:

• Review and summarization of previously published data on neuroleptic drug effects.
• Assessment of orexin A's role in modulating body temperature and sympathetic activity.
• Analysis of interactions between specific neuroleptic drugs (haloperidol, clozapine, olanzapine, risperidone, quietapine) and the orexinergic system.

Main Results:

• Orexin A's hyperthermic effects are modulated by several neuroleptic drugs.
• Haloperidol reduces orexin A-mediated hyperthermia, while clozapine and olanzapine block it.
• Risperidone enhances orexin A-mediated body temperature elevation, and quietapine delays these effects.

Conclusions:

• Neuroleptic drugs appear to influence body temperature control via activation of the orexinergic system.
• Understanding these interactions is crucial for predicting and managing metabolic side effects like weight gain.
• Personalized selection of antipsychotic medications, considering their specific risks and benefits, is essential for patient health and preventing metabolic disorders.